You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
Cerebral gliomas account for 45% of all primary central nervous system (CNS) tumors. The median survival after the initial diagnosis of glioblastoma (GBM) is only 15 months, and less than 10% of patients survive three years post-diagnosis. Surgical treatment followed by adjuvant therapies such as radiotherapy and chemotherapy represents the classical strategy in glioma management. The revised WHO 2016 classification now distinguishes the oligodendrogliomas with 1p19q codeletion and IDH mutation from the astrocytomas with or without IDH mutations, thereby creating homogenous and pathologically distinct subgroups. While the status of gene expression and mutations define components of GBM subtypes, it was also found that response to therapies was different for each subtype, suggesting that personalized treatment based on genomic alterations could lead to a more favorable outcome for this disease.
We are pleased to introduce the 2021 Frontiers in Oncology: Editor’s Pick collection, showcasing articles stimulating interest in the field, carefully selected by our Field Chief Editor, Prof. Giuseppe Giaccone, of Weill Cornell Medicine. With this ebook we aim to highlight and disseminate important findings across the domains of cancer research, capturing the multidisciplinary and inclusive approach our journal takes towards advancing the field of oncology and supporting the global effort towards improved quality of life and patient survival. 2021 was a year which saw our highest journal impact factor yet, international community growth, and a record-breaking number of articles to choose from. We wish to elevate the contributions made by authors, encourage readership and innovation through our open-access philosophies, and thank our Editorial Board for their continued hard work and collaboration.
None
Der deutsche »Berufsverbrecher« Otto Küsel, der im Mai 1940 als Häftling Nr. 2 nach Auschwitz kam, hat als Funktionshäftling Hunderten von polnischen Häftlingen das Leben gerettet, indem er sie vor der »Vernichtung durch Arbeit« bewahrte. 1942 gelang Küsel eine der spektakulärsten Fluchten aus Auschwitz. Neun Monate lebte er im Untergrund; der spätere polnische Außenminister und Friedenspreisträger des deutschen Buchhandels, Władysław Bartoszewski, wollte ihm in dieser Zeit gefälschte Papiere besorgen. Erneut verhaftet, überlebte Küsel Folter und den Todesmarsch. Nach dem Krieg wurde ihm die polnische Staatsbürgerschaft ehrenhalber angeboten. Im ersten Auschwitz-Prozess in Frankfurt am Main hat er als Zeuge ausgesagt. In Polen ist Otto Küsel ein Held, in Deutschland bis heute so gut wie unbekannt. Sebastian Christ, der 20 Jahre lang auf Küsels Spuren geforscht hat, erzählt seine erschütternde wie heldenhafte Geschichte.
None
None